KR20170137738A - 부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조방법 - Google Patents

부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조방법 Download PDF

Info

Publication number
KR20170137738A
KR20170137738A KR1020177028535A KR20177028535A KR20170137738A KR 20170137738 A KR20170137738 A KR 20170137738A KR 1020177028535 A KR1020177028535 A KR 1020177028535A KR 20177028535 A KR20177028535 A KR 20177028535A KR 20170137738 A KR20170137738 A KR 20170137738A
Authority
KR
South Korea
Prior art keywords
buprenorphine
free base
mixture
acetate salt
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177028535A
Other languages
English (en)
Korean (ko)
Inventor
씨. 프레데릭 엠. 헌틀리
에릭 웨인 카타이스토
헬게 알프레드 리슈
아르차나 샤르마
제이크 래리 스티미스트
Original Assignee
로드스 테크놀로지즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로드스 테크놀로지즈 filed Critical 로드스 테크놀로지즈
Publication of KR20170137738A publication Critical patent/KR20170137738A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020177028535A 2015-03-10 2016-03-09 부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조방법 Ceased KR20170137738A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131114P 2015-03-10 2015-03-10
US62/131,114 2015-03-10
PCT/IB2016/051332 WO2016142877A1 (en) 2015-03-10 2016-03-09 Acetate salt of buprenorphine and methods for preparing buprenorphine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011729A Division KR20200045010A (ko) 2015-03-10 2016-03-09 부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조 방법

Publications (1)

Publication Number Publication Date
KR20170137738A true KR20170137738A (ko) 2017-12-13

Family

ID=55524412

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177028535A Ceased KR20170137738A (ko) 2015-03-10 2016-03-09 부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조방법
KR1020207011729A Ceased KR20200045010A (ko) 2015-03-10 2016-03-09 부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207011729A Ceased KR20200045010A (ko) 2015-03-10 2016-03-09 부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조 방법

Country Status (19)

Country Link
US (6) US10406152B2 (enExample)
EP (1) EP3283490A1 (enExample)
JP (2) JP6660399B2 (enExample)
KR (2) KR20170137738A (enExample)
CN (1) CN107660207B (enExample)
AR (1) AR103902A1 (enExample)
AU (2) AU2016230750B2 (enExample)
BR (1) BR112017019357A2 (enExample)
CA (2) CA3104099A1 (enExample)
CO (1) CO2017009130A2 (enExample)
EA (1) EA201792014A1 (enExample)
IL (1) IL254384A0 (enExample)
MA (1) MA45902A (enExample)
MX (1) MX2017011606A (enExample)
NZ (1) NZ735736A (enExample)
PH (1) PH12017501641A1 (enExample)
SG (1) SG11201707350TA (enExample)
TW (2) TW202037597A (enExample)
WO (1) WO2016142877A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ711538A (en) 2013-03-15 2017-03-31 Univ Leland Stanford Junior Benzylisoquinoline alkaloids (bia) producing microbes, and methods of making and using the same
US11124814B2 (en) 2013-11-04 2021-09-21 The Board Of Trustees Of The Leland Stanford Junior University Benzylisoquinoline alkaloid (BIA) precursor producing microbes, and methods of making and using the same
CA3104099A1 (en) 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
WO2016179296A1 (en) 2015-05-04 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Benzylisoquinoline alkaloid (bia) precursor producing microbes, and methods of making and using the same
CA2983445A1 (en) 2015-05-08 2016-11-17 The Board Of Trustees Of The Leland Stanford Junior University Methods of producing epimerases and benzylisoquinoline alkaloids
AU2017345328C1 (en) 2016-10-18 2023-03-02 Antheia, Inc. Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
WO2019028390A1 (en) 2017-08-03 2019-02-07 Antheia, Inc. ALKALOID BENZYLISOQUINOLEIN GENETICALLY MODIFIED EPIMERASES AND METHODS FOR PRODUCING BENZYLISOQUINOLINE ALKALOIDS
NZ766474A (en) * 2018-05-11 2023-03-31 Alar Pharmaceuticals Inc Long-acting injectable formulations and crystalline forms of buprenorphine derivatives
EP3934765A4 (en) 2019-03-08 2022-11-30 The Board Of Trustees Of The Leland Stanford Junior University TROPANE ALKALOID (TA) PRODUCING NON-PLANT HOST CELLS AND METHODS FOR THEIR MANUFACTURE AND USE
IL317873A (en) * 2022-06-24 2025-02-01 Alar Pharmaceuticals Inc Stable pharmaceutical composition of buprenorphine and method of preparation and use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275638A (en) * 1966-09-27 Chjcoo-
US2191786A (en) 1938-03-18 1940-02-27 C A Miketta Continuous process for making adipic acid
BE466549A (enExample) 1945-07-17
US3355486A (en) 1965-01-08 1967-11-28 Fmc Corp Continuous process of synthesizing amino-iminomethane-sulfinic acid
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1312447A (en) 1969-05-14 1973-04-04 Nat Res Dev Method of continuous addition of a component to a chemical or biological system and apparatus therefor
US4217287A (en) 1971-10-06 1980-08-12 Gulf Research & Development Company Epoxidation of alpha-olefins
US3936462A (en) * 1972-05-26 1976-02-03 Sterling Drug Inc. 1,2,3,4,5,6-Hexahydro-1-oxo or hydroxy-3-acyl-2,6-methano-3-benzazocines and corresponding 1-esters thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
GB1520139A (en) 1976-06-08 1978-08-02 Ferranti Ltd Gyroscopic apparatus
US4362870A (en) * 1980-01-16 1982-12-07 Regents Of The University Of Minnesota Selective opioid receptor alkylating agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4830028A (en) 1987-02-10 1989-05-16 R. J. Reynolds Tobacco Company Salts provided from nicotine and organic acid as cigarette additives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
TW452907B (en) 1999-11-22 2001-09-01 Winbond Electronics Corp Testing device and method of positive mobile ion contamination
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US7560445B2 (en) 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
CA2671518C (en) 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
EP2114953B1 (en) 2006-12-11 2012-06-06 Alcon Research, Ltd. Process for preparing substantially pure fluorescein
WO2010016219A1 (ja) * 2008-08-05 2010-02-11 株式会社メドレックス 塩基性薬効成分の脂肪酸塩、安息香酸塩を含有する外用剤とその製造方法
WO2011005452A1 (en) * 2009-07-09 2011-01-13 Mallinckrodt Inc. Method for the enrichment of buprenorphine using chromatographic techniques
PL2621496T5 (pl) * 2010-09-30 2019-05-31 Astrazeneca Ab Krystaliczny koniugat naloksol-peg
TW201338813A (zh) 2011-12-12 2013-10-01 Lohmann Therapie Syst Lts 經皮遞送系統
HK1206978A1 (en) 2012-04-17 2016-01-22 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
EP2941433B1 (en) * 2012-12-31 2019-08-07 Rhodes Technologies Process for preparing 7 -substituted 6 ,14 -ethenomorphinans and 7 -substituted 6 ,14 -ethanomorphinans
AU2014276910B2 (en) 2013-06-04 2017-03-09 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
CN103408553B (zh) * 2013-08-20 2016-02-03 宜昌人福药业有限责任公司 一种氢吗啡酮酸式盐的精制工艺
US8846923B1 (en) * 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
CA3104099A1 (en) * 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine

Also Published As

Publication number Publication date
EA201792014A1 (ru) 2018-01-31
KR20200045010A (ko) 2020-04-29
CN107660207B (zh) 2020-09-29
JP6660399B2 (ja) 2020-03-11
TWI699367B (zh) 2020-07-21
PH12017501641A1 (en) 2018-02-12
US10278967B2 (en) 2019-05-07
NZ735736A (en) 2019-02-22
US20190314364A1 (en) 2019-10-17
US20180235955A1 (en) 2018-08-23
MA45902A (fr) 2019-06-19
CO2017009130A2 (es) 2017-11-21
AU2019203308A1 (en) 2019-05-30
CA3104099A1 (en) 2016-09-15
TW202037597A (zh) 2020-10-16
AU2016230750B2 (en) 2019-05-30
CN107660207A (zh) 2018-02-02
JP2018507882A (ja) 2018-03-22
MX2017011606A (es) 2017-10-26
CA2977732A1 (en) 2016-09-15
IL254384A0 (en) 2017-11-30
US20180162866A1 (en) 2018-06-14
US10874662B2 (en) 2020-12-29
EP3283490A1 (en) 2018-02-21
US20170197975A1 (en) 2017-07-13
US20190298713A1 (en) 2019-10-03
US10406152B2 (en) 2019-09-10
US9926329B2 (en) 2018-03-27
TW201639856A (zh) 2016-11-16
WO2016142877A1 (en) 2016-09-15
CA2977732C (en) 2021-02-23
AU2016230750A1 (en) 2017-10-12
BR112017019357A2 (pt) 2018-06-05
AR103902A1 (es) 2017-06-14
SG11201707350TA (en) 2017-10-30
US10835528B2 (en) 2020-11-17
US20210046066A1 (en) 2021-02-18
JP2020033359A (ja) 2020-03-05

Similar Documents

Publication Publication Date Title
US10874662B2 (en) Acetate salt of buprenorphine and methods for preparing buprenorphine
US10519176B2 (en) Crystalline forms
TWI545124B (zh) ６，７－不飽合－７－胺甲醯基嗎啡喃衍生物之結晶及其製造方法
WO2011083304A1 (en) Prodrugs of opioids and uses thereof
JP2005525367A (ja) 塩酸イリノテカンの結晶多形
JP6275644B2 (ja) Ｎ−［２−（｛２−［（２Ｓ）−２−シアノピロリジン−１−イル］−２−オキソエチル｝アミノ）−２−メチルプロピル］−２−メチルピラゾロ［１，５−ａ］ピリミジン−６−カルボキサミドの結晶
US20060046993A1 (en) Crystalline polymorphic form of irinotecan hydrochloride
RU2515557C1 (ru) Фармацевтическая соль 8-метил-7-[5-метил-6-(метиламино)-3-пиридинил]-1-циклопропил-4-оксо-1,4-дигидро-3-хинолинкарбоновой кислоты, ее содержащая фармацевтическая композиция, лекарственное средство и способ лечения или профилактики бактериальных инфекций с помощью вышеуказанной соли
MXPA06012793A (es) Formas polimorficas de nateglinida.
JP4829120B2 (ja) イリノテカン酸付加塩
JPWO2000009530A1 (ja) エリスロマイシン誘導体の製造法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171010

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171011

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190118

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191015

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190118

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20191015

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190718

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20171011

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200122

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200113

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20191015

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190718

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20190118

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171011

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200422

PJ0201 Trial against decision of rejection

Patent event date: 20200422

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20200122

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20191015

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2020101001157

Request date: 20200422

J301 Trial decision

Free format text: TRIAL NUMBER: 2020101001157; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20200422

Effective date: 20211022

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20211022

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20200422

Decision date: 20211022

Appeal identifier: 2020101001157